HCA HCA Healthcare
After the rally, HCA's scale franchise trades near fair value, so the margin of safety is gone.
The story
HCA is the largest US for-profit hospital operator, with dense local market clusters that give it pricing power with payers, procurement scale, and operating leverage that smaller systems can't match. It is a mature, cash-generative compounder that grows through volume, acuity, and steady bolt-on capacity, and it returns capital through aggressive buybacks. The main threats are policy: Medicaid cuts, the expiry of exchange subsidies, and site-neutral payment reform. Recent results show resilient volumes and margins holding near 16%.
Drivers are essentially unchanged. Y1 growth nudges up from 5.5% to 6% (not a material move) because TTM revenue of 78.0B is running ahead of the 75.6B fiscal year. Target margin stays at 15.5%, just under the 15.6% TTM, to allow for payer-mix and policy drag. Sales-to-capital of 1.85 and beta of 1.05 still fit a capital-heavy, leveraged operator carrying about 45B of net debt.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 8y |
| Target operating margin | 15.5% |
| Years to target margin | 7 |
| Sales-to-capital | 1.85 |
| Beta | 1.05 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 8.5% |
Valuation bridge
| PV of explicit FCFF | 53.76B |
| PV of terminal value | 98.08B |
| Equity value | 100.03B |
| ÷ shares → per share | $462.05 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 82.69B | 6.0% | 15.6% | 10.21B | 2.53B | 7.68B | 7.07B |
| 2 | 87.24B | 5.5% | 15.6% | 10.76B | 2.46B | 8.30B | 7.04B |
| 3 | 91.60B | 5.0% | 15.6% | 11.29B | 2.36B | 8.93B | 6.97B |
| 4 | 95.73B | 4.5% | 15.6% | 11.78B | 2.23B | 9.56B | 6.87B |
| 5 | 99.56B | 4.0% | 15.5% | 12.24B | 2.07B | 10.17B | 6.73B |
| 6 | 103.04B | 3.5% | 15.5% | 12.66B | 1.88B | 10.77B | 6.56B |
| 7 | 106.13B | 3.0% | 15.5% | 13.02B | 1.67B | 11.35B | 6.37B |
| 8 | 108.78B | 2.5% | 15.5% | 13.35B | 1.43B | 11.91B | 6.15B |
Key risks
- Medicaid funding cuts and loss of enhanced ACA subsidies raise the uninsured mix and bad debt
- Site-neutral payment reform and commercial payer pushback compress pricing
- Labor cost inflation and nurse staffing shortages squeeze margins, and roughly 45B of net debt amplifies equity downside
Catalysts
- Continued buybacks shrinking the share count at a mid-single-digit annual pace
- Policy clarity on exchange subsidies and Medicaid supplemental payments that removes the regulatory overhang